Dave Moorhouse was elated when he was informed that a microchip provider had information on the whereabouts of his stolen dog. This joy soon faded when the company informed him that it could not divulge the Jack Russell terrier's location because it would breach the Data Protection Act. Last week a court agreed with the chip company and refused Mr Moorhouse's request for a court order compelling them to reveal the name and address of the new owners. Steven Wildridge, managing director of the chip company said: “This is not a choice, it’s an obligation under the Data Protection Act. If the individuals involved do not want us to pass on their details to the original owner then we cannot do so unless compelled to following a criminal or civil proceeding."

An anonymous reader writes "A Wisconsin priest has God on his car but Best Buy's lawyers on his back. Father Luke Strand at the Holy Family Parish in Fond Du Lac says he has received a cease-and-desist letter from the electronics retailer. From the article: 'At issue is Strand's black Volkswagen Beetle with door stickers bearing the name "God Squad" in a logo similar to that of Best Buy's Geek Squad, a group of electronics troubleshooters. Strand told the Fond du Lac Reporter that the car is a creative way to spur discussion and bring his faith to others. Best Buy Co. tells the Milwaukee Journal Sentinel that it appreciates what Strand is trying to do, but it's bad precedent to let groups violate its trademarks.'"

the_arrow writes "As a celebration of the 25th anniversary of the Amiga computer, Hyperion Entertainment has made a video using the Gource CVS visualization software showing a time-compressed version of 25 years of Amiga development, from the early days of AmigaOS 1.0 to the present. Personal commentary added by one of the current core full-time AmigaOS developers, Hans-Joerg Frieden (a.k.a. 'Rogue')."

Russian photographer Sergey Larenkov has taken old World War II photos and photoshopped them over the locations in present day. The scenes from places like Prague, Vienna, and Moscow are incredibly well done and a neat way to appreciate history.

Meshach writes "A new plug-in for Outlook will warn you if an email you are about to send is 'too emotional.' Basically the plug-in scans the email for emotions such as elation, humiliation, excitement and fear. A user can set how much emotion they want to allow in their messages and if exceeded the threshold a warning will pop up."

In a decision that was reversed as soon as someone with half a brain in their PR department learned about it, Verizon charged a widow a $350 early termination fee. After the death of her marine husband, Michaela Brummund decided to move back to her home town to be with her family. Verizon doesn't offer any coverage in the small town so Michaela tried to cancel her contract, only to be hit with an early termination fee. From the article: "'I called them to cancel. I told them the situation with my husband. I even said I would provide a death certificate,' Michaela said."

Medical doctor and writer Atul Gawande gave the commencement address recently at Stanford's School of Medicine. In it he lays out very precisely and in a nonpartisan way what is wrong with the institution of medical care in the US — why it is both so expensive and so ineffective at delivering quality care uniformly across the board. "Half a century ago, medicine was neither costly nor effective. Since then, however, science has... enumerated and identified... more than 13,600 diagnoses — 13,600 different ways our bodies can fail. And for each one we've discovered beneficial remedies... But those remedies now include more than six thousand drugs and four thousand medical and surgical procedures. Our job in medicine is to make sure that all of this capability is deployed, town by town, in the right way at the right time, without harm or waste of resources, for every person alive. And we're struggling. There is no industry in the world with 13,600 different service lines to deliver. ... And then there is the frightening federal debt we will face. By 2025, we will owe more money than our economy produces. One side says war spending is the problem, the other says it's the economic bailout plan. But take both away and you've made almost no difference. Our deficit problem — far and away — is the soaring and seemingly unstoppable cost of health care. ... Like politics, all medicine is local. Medicine requires the successful function of systems — of people and of technologies. Among our most profound difficulties is making them work together. If I want to give my patients the best care possible, not only must I do a good job, but a whole collection of diverse components must somehow mesh effectively. ... This will take science. It will take art. It will take innovation. It will take ambition. And it will take humility. But the fantastic thing is: This is what you get to do."

The Flash platform has been taking body blows lately. First Apple, then Scribd, publicly abandon it; now ARM's marketing VP is blaming a delay in ARM smartbooks on the continuing unsuitability of Flash for the subnotebook market. But how ready is HTML5 to take over from Flash? Tim Bray offers a cautionary appraisal of the not-yet-a-standard's state of grace. While Flash may be on the way out (or so legions of its detractors hope), it is still important in many corners of the Web. Here a branding expert demonstrates that the sites of 10 out of 10 leading worldwide brands don't display on the iPad — because they're coded in Flash, of course.

reverseengineer writes "The US Food and Drug Administration has given its first first approval for a therapeutic cancer vaccine. In a clinical trial 'involving 512 men, those who got Provenge (sipuleucel-T) had a median survival of 25.8 months after treatment, while those who got a placebo lived a median of 21.7 months. After three years, 32 percent of those who got Provenge were alive, compared with 23 percent of those who got the placebo. ... "The big story here is that this is the first proof of principle and proof that immunotherapy works in general in cancer, which I think is a huge observation," said Dr. Philip Kantoff, chief of solid tumor oncology at the Dana-Farber Cancer Institute in Boston and the lead investigator in Dendreon's largest clinical trial for the drug. "I think this is a very big thing and will lead to a lot more enthusiasm for the approach."'"